Banner: investors

News Releases

PURE Bioscience to Present at 2017 SeeThru Equity Investor Conference

September 14, 2017

SAN DIEGO (September 14, 2017) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial,  today announced that the Company will present at the 2017 SeeThru Equity Investor Conference at 11am EDT on September 27, 2017 at the Grand Hyatt Hotel, New York.

Hank R. Lambert, CEO of PURE, will provide business updates on the commercialization of the Company’s two food safety antimicrobial products to combat foodborne illness:

  • PURE® Hard Surface disinfectant:

    • Sales to restaurant chains (including Chipotle Mexican Grill), and expanding use with 40+ national food processors/manufacturers

    • Newly developed sanitization solution for food transportation vehicles

  • PURE Control® (FDA/USDA approved direct food contact processing aid):

    • Sales to fresh produce processors; sales and marketing to raw poultry parts processors

    • Progress update of USDA in-plant trials for approval for raw poultry OLR whole bird processing

    • Est. combined $650M+ US market opportunity for produce and poultry processing aids

SDC test results demonstrate materially significant reduction in Salmonella, Listeria and E. coli contamination in fresh produce; and dramatic reduction of Salmonella contamination in raw poultry.

The presentation will be webcast live with slides (and available for replay) and can be accessed at: https://www.purebio.com/investors/events-presentations/.

About SeeThru Equity

Since its founding in 2011, SeeThru Equity has been committed to its core mission:  providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThru Equity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThru Equity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThru Equity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet.

About PURE Bioscience, Inc.  

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements   

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; the Company’s ability to raise funds necessary to support its continued operations and the implementation of its business plan; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2016, second quarter ended January 31, 2017, and third quarter ended April 30, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contacts:

 

Hank Lambert, CEO

Terri MacInnis, VP of IR

Tom Hemingway

PURE Bioscience, Inc.

Bibicoff + MacInnis, Inc.

Redwood Investment Group

619-596-8600 ext.103

818-379-8500

714-978-4425

hlambert@purebio.com

terri@bibimac.com

tomh@redwoodfin.com